Since CHK1 is the effector kinase of ATR, several cellular functions are shared between these kinases, and the rationales behind exploring CHK1 inhibitors for cancer therapy are hence similar to those for ATR inhibitors (Table 1; Forment and O'Connor 2018). Here, ATR is linked to cancer.